Company news
Oxford Nanopore Technologies Plc (LSE:ONT) news
Oxford Nanopore Technologies Plc news releases on 6ix. Latest, Jan 13, 2025: SIP PDMR Notification and Correction
Press releases — page 2
SIP PDMR Notification and Correction
January 13, 2025
Presentation at 43rd Annual J.P. Morgan Conference
January 7, 2025
Directorate Change - Appointment of SID
December 16, 2024
Class A LAT share - Director/PDMR Notification
November 28, 2024
Oxford Nanopore and UK Biobank collaboration
November 27, 2024
Proposed cancellation of LAT shares
November 26, 2024
Changes to the senior leadership team
November 11, 2024
Approval of the transfer of listing category
November 6, 2024
Issue of Capital and Total Voting Rights
November 1, 2024
Admission to Trading on the London Stock Exchange
October 14, 2024
New issue in connection with LTIP awards
October 10, 2024
Notice of intention to transfer listing category
October 8, 2024
Block Listing Interim Review
October 7, 2024
Daniel Mahony appointed as Non-Executive Director
October 1, 2024
Seeks discovery into expected breach of contract
September 10, 2024
Oxford Nanopore to present at upcoming conferences
September 5, 2024
Interim results for the 6 months ended 30 June 24
September 3, 2024
Notice of Interim Results Presentation
August 30, 2024
Director Declaration
August 9, 2024
Admission of Ordinary Shares & Total Voting Rights
August 5, 2024
Oxford Nanopore: Singapore Precision Medicine prog
August 5, 2024
Investment from Novo Holdings and Equity Issue
August 1, 2024
Investment from Novo Holdings and proposed placing
July 31, 2024
Half Year Trading Update
July 24, 2024
Plasmidsaurus collaboration and contract expansion
July 23, 2024
Appointment of corporate broker
July 16, 2024
Total Voting Rights
July 1, 2024
Issue of Equity
June 19, 2024
Result of AGM; Director Responsibilities
June 10, 2024
PDMR/PCA Notification
June 7, 2024
Study unlocks insights into disease and longevity
April 12, 2024
LTIP and DBP; Director/PDMR Notification
April 12, 2024
Oxford Nanopore to Present at Barclays Conference
March 12, 2024
FY23 Preliminary Results
March 6, 2024
Directorate Change
February 29, 2024
Expansion of leadership team
January 22, 2024
Employee Stock Purchase Plan - PDMR Notification
January 11, 2024
FY23 trading update
January 9, 2024
Presentation at 42nd Annual J.P. Morgan Conference
January 3, 2024
Director/PDMR Shareholding (ESPP)
January 2, 2024
Appointment of Two Non-Executive Directors
December 19, 2023
Nanopore Community Meeting Technology Update
December 7, 2023
National Australian rare disease programme
November 30, 2023
Participation in upcoming investor conferences
November 13, 2023
Apple showcases Oxford Nanopore in M3 launch
October 31, 2023
Mayo Clinic and Oxford Nanopore collaboration
October 19, 2023
Capital Markets Day - ONT expands into clinical
October 19, 2023
bioMérieux makes investment in Oxford Nanopore
October 19, 2023
Presentation at the Morgan Stanley Conference
September 12, 2023
Interim results for the 6 months ended 30 June 23
September 6, 2023